Compliance Radar
Who was sanctioned, and for what?
Fines, court rulings and incidents from Europe, North America, Latin America, Asia-Pacific, Middle East and Africa: 2,207 cases from 44 jurisdictions, each with an official source and checked against that source before publication. Filter by country, area of law and sector. Click a chart to drill down one level.
Click a bar to drill down one level.
Where?
by levelWhat for?
by area of lawAll areas of law
- Bribery and corruption €232.7m 57 % · 15 cases
- Capital markets and financial supervision €166.7m 41 % · 1 case
- Data protection €7.16m 2 % · 1 case
- Sanctions and export control €1.47m 0 % · 1 case
- Information security and cyber €1.38m 0 % · 1 case
- Whistleblower protection €1.26m 0 % · 1 case
- Health and safety and employment law €612,121 0 % · 1 case
- Consumer protection and online retail €128,557 0 % · 1 case
- Competition law – 0 % · 1 case
- AI and digital regulation – 0 % · 1 case
Who?
by company- Becton, Dickinson and Company (BD) €166.7m 41 % · 1 case
- Anonymised companies €120.2m 29 % · 10 cases
- Access DX Laboratory, LLC €31.7m 8 % · 1 case
- Advanced Pathology Solutions PLLC und APS MSO LLC €25.9m 6 % · 1 case
- C.R. Bard, Inc.; Liberator Medical Supply, Inc.; Liberator Holdings; Rochester Medical Corporation €16.3m 4 % · 1 case
- NUWAY Alliance, Inc. €15.8m 4 % · 1 case
- Oroville Hospital €9.77m 2 % · 1 case
- NeoGenomics Laboratories Inc. €8.59m 2 % · 1 case
- Modern Nuclear Inc. €7.12m 2 % · 1 case
- New York-Presbyterian Hudson Valley Hospital €5.79m 1 % · 1 case
- 5 more€3.5m
When?
per year, by date of decision| Period | Cases | Total |
|---|---|---|
| 2023 | 4 | €71.5m |
| 2024 | 8 | €225.1m |
| 2025 | 4 | €38.1m |
| 2026 | 8 | €76.7m |
24 cases
14 Aug 2026 Plexon, Inc.Plexon: brain research recording systems to listed Chinese military medical academy – 1.7 million USD suspended €1.47m
The neurotechnology company from Dallas, described by the Bureau of Industry and Security (BIS, the export control agency of the US Department of Commerce) as small, delivered neural data acquisition systems (“OmniPlex”) and accessories worth around 179,000 USD on eight occasions in 2022/23 via its Asian distributor to the Chinese Academy of Military Medical Sciences, which has been on the Entity List (the US export control list of restricted parties) since December 2021. The penalty of 1.7 million USD is suspended for five years and then waived, provided that Plexon submits an external audit of its export compliance programme on time and commits no further violations; a five-year denial of export privileges is likewise suspended, and Plexon must also provide export control training.
Screen orders placed via distributors against the Entity List before production – research equipment can also end up with listed military institutions.
Entity List screening for orders via distribution partners
Missing or inadequate training played a role in the decision.
- Authority / court
- U.S. Department of Commerce, Bureau of Industry and Security (BIS)
- Area of law
- Sanctions and export control · Export control and dual-use goods
- Legal basis
- Export Administration Regulations, 15 C.F.R. § 764.2(a), § 744.11
- Action
- Fine
- Status of proceedings
- final
- Sector
- Healthcare
- Mitigating circumstances
- Penalty and denial of export privileges fully suspended for five years, conditional on an external export control audit.
- Published
- 14 Aug 2026
Original amount 1,700,000 USD, converted at the ECB reference rate of 14 Aug 2026.
- BIS Reaches Administrative Enforcement Settlement with Plexon, Inc. Press release of an authority
- Order Relating to Plexon, Inc., Settlement Agreement und Proposed Charging Letter Decision of an authority
Checked against the official source on 28 Sep 2026 · Direct link
Report an error
30 Jul 2026 Access DX Laboratory, LLCAccess DX Laboratory: 36.4 million USD – kickbacks for unnecessary genetic tests €31.7m
The Houston laboratory allegedly paid kickbacks and billed Medicare and Medicaid for medically unnecessary genetic tests. The settlements with the laboratory and other parties add up to 36.4 million USD (combined total); the laboratory is subject to a Corporate Integrity Agreement.
Commission models for intermediaries who bring in orders or patients are a classic gateway for bribery.
Remuneration of intermediaries and referrers
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Liability of senior managers
- Measures against individuals are not reported here.
Original amount 36,400,000 USD, converted at the ECB reference rate of 30 Jul 2026.
- HHS-OIG Enforcement Actions: Vergleiche mit Access DX Laboratory und weiteren Beteiligten (30.07.2026) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 3 · Direct link
Report an error
20 Jul 2026 NeoGenomics Laboratories Inc.NeoGenomics: 9.8 million USD after self-disclosure – discounted consulting for referring physicians €8.59m
The Florida laboratory provided referring physicians with consulting services below market value and paid independent consultants referral-based remuneration for recruiting physicians. Following a self-disclosure, NeoGenomics paid 9,813,260 USD.
Free or discounted services are also benefits – like cash payments, they belong in the anti-corruption review.
Services with monetary value provided to customers below market value
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Mitigating circumstances
- Self-disclosure of the remuneration arrangements.
Original amount 9,813,260 USD, converted at the ECB reference rate of 20 Jul 2026.
- HHS-OIG Enforcement Actions: Florida Laboratory Agrees to Pay $9.8M … Self-Disclosure of Compensation Arrangements (20.07.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
17 Jun 2026 Advanced Pathology Solutions PLLC und APS MSO LLCAdvanced Pathology Solutions: 30 million USD for kickbacks and unnecessary laboratory tests €25.9m
The Arkansas pathology laboratory and its management company allegedly granted unlawful kickbacks and ordered medically unnecessary tests. The settlement of 30 million USD is a joint payment by all settling parties; the laboratory entered into a Corporate Integrity Agreement.
Where services are sold through referrals, all benefits to referrers belong in a central approval and review procedure.
Benefits to clients in healthcare
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Liability of senior managers
- Measures against individuals are not reported here.
Original amount 30,000,000 USD, converted at the ECB reference rate of 17 Jun 2026.
- HHS-OIG Enforcement Actions: Vergleich mit Advanced Pathology Solutions (17.06.2026) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 3 · Direct link
Report an error
2 Jun 2026 Ascension Health Alliance; AmSurg LLC / Ambulatory Topco LLCAscension/AmSurg: seven ambulatory surgery centres must be sold Order
The non-profit hospital group Ascension wanted to acquire AmSurg for 3.9 billion USD. Owing to overlaps in outpatient surgery in five regions, the Federal Trade Commission (FTC) requires the sale of seven AmSurg centres to SC Affiliates and a gastroenterology practice, as well as transitional support.
Non-profit healthcare providers are also subject to merger control – regional market shares determine divestitures.
- Authority / court
- Federal Trade Commission (FTC)
- Area of law
- Competition law · Merger control
- Legal basis
- Section 7 Clayton Act; Section 5 FTC Act (Consent Order)
- Action
- Order
- Status of proceedings
- unknown
- Sector
- Healthcare
- Employees
- 10,000 or more
- FTC Requires Divestiture of Ambulatory Surgery Centers … Ascension Health-AmSurg Deal (02.06.2026) Press release of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
1 May 2026 Modern Nuclear Inc.Modern Nuclear: 8.33 million USD – excessive supervision fees paid to referring cardiologists €7.12m
The Californian provider of mobile PET scans allegedly paid referring cardiologists excessive fees for supervising the examinations in order to secure referrals. The settlement of 8,334,350.71 USD plus revenue-based payments is based on ability to pay; in addition, there is a Corporate Integrity Agreement.
Remuneration of business partners who refer work must correspond to the market value of the service – any overpayment acts as a bribe.
Checking fee agreements with referrers for market conformity
- Authority / court
- U.S. Department of Justice / U.S. Attorney's Office, Central District of California
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 8,334,350.71 USD, converted at the ECB reference rate of 30 Apr 2026.
- HHS-OIG Enforcement Actions: Mobile PET Scan Provider to Pay $8.33 Million … Unlawful Kickbacks to Medical Practices (01.05.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
17 Mar 2026 Balt SAS / Balt USA LLCMedical technology: DOJ declination for Balt SAS after bribery of a hospital physician €1.05m
Through sham consultancy agreements, fictitious invoices and purported bonus payments, around 602,000 USD in bribes flowed from 2017 to 2023 via a Belgian consultant to a physician in a senior position at a French public hospital, so that the hospital would purchase embolisation coils from Balt. The DOJ declined to prosecute on account of voluntary self-disclosure, cooperation and remediation (declination of 17 March 2026); Balt is disgorging 1,214,797 USD in profits.
Physicians at public hospitals are public officials – consultancy agreements with them require documented services and approval by the compliance function.
Benefits to physicians in the public healthcare sector, sham consultancy agreements
- Authority / court
- U.S. Department of Justice (Criminal Division, Fraud Section)
- Area of law
- Bribery and corruption · Bribery of public officials
- Legal basis
- FCPA; Corporate Enforcement and Voluntary Self-Disclosure Policy (Declination)
- Action
- Disgorgement of profits
- Status of proceedings
- final
- Sector
- Healthcare
- Culpability
- intentional
- Mitigating circumstances
- Voluntary self-disclosure (including to the French national financial prosecutor's office, PNF), full cooperation, timely remediation, disciplinary measures, parallel resolution in France.
- Liability of senior managers
- Measures against individuals are not reported here.
- Published
- 19 Mar 2026
Original amount 1,214,797 USD, converted at the ECB reference rate of 17 Mar 2026.
- U.S. Department of Justice, Pressemitteilung zu Balt SAS (Entscheidung 2026) Press release of an authority
- Communiqué de presse du procureur de la République financier – CJIP BALT USA (19.03.2026) Press release of an authority
- DOJ Criminal Division, Fraud Section: Declination Letter Re: Balt SAS (17.03.2026) Decision of an authority
Checked against the official source on 28 Sep 2026 · Version 3 · Direct link
Report an error
5 Mar 2026 Allin IP DX LLCAllin IP DX: 980,000 USD after self-disclosure over paid referral marketers €843,519
Between January and June 2023, the Sarasota laboratory paid independent marketers to steer laboratory samples from Medicare beneficiaries to it. It self-disclosed the conduct, cooperated extensively and paid 980,000 USD.
Early self-disclosure limits the damage – but this requires the compliance function to actually get to see problematic sales contracts.
Success-based remuneration of sales partners
- Authority / court
- U.S. Attorney's Office, Middle District of Florida
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Mitigating circumstances
- Voluntary self-disclosure, detailed disclosure and cooperation.
Original amount 980,000 USD, converted at the ECB reference rate of 5 Mar 2026.
- HHS-OIG Enforcement Actions: Sarasota Lab Agrees to Pay $980,000 to Resolve False Claims Act Violations (05.03.2026) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
22 Dec 2025 New York-Presbyterian Hudson Valley HospitalNYP Hudson Valley Hospital: 6.8 million USD for payments to referring practice €5.79m
The hospital (until 2015 Hudson Valley Hospital Center) allegedly paid an oncology practice in Westchester millions of dollars to induce it to refer patients to the hospital; the hospital billed the services to Medicare and Medicaid. The U.S. Attorney’s Office filed a complaint and at the same time concluded a settlement of 6.8 million USD.
Cooperation agreements between hospitals and office-based practices must properly document services and remuneration – otherwise payments are treated as referral bonuses.
Payments to referrers in hospitals
- Authority / court
- U.S. Attorney's Office, Southern District of New York
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 6,800,000 USD, converted at the ECB reference rate of 22 Dec 2025.
- HHS-OIG Enforcement Actions: U.S. Attorney Announces $6.8 Million Settlement With New York-Presbyterian Hudson Valley Hospital … (22.12.2025) Enforcement database of an authority
Checked against the official source on 25 Sep 2026 · Direct link
Report an error
3 Dec 2025 Southern Health Solutions, Inc. (Next Medical / NextMed)NextMed: FTC settlement over allegations of hidden costs and review manipulation €128,557
According to the FTC, the telemedicine company advertised GLP-1 weight-loss programmes with monthly prices that did not include medication, laboratory costs and medical consultations, concealed the minimum term and cancellation fees, published fake testimonials from employees and relatives, and induced customers to delete negative reviews by offering vouchers or refunds. Under the final settlement order, the company is paying 150,000 USD jointly with other liable parties (joint payment), which is earmarked for refunds.
"Buying off" negative reviews with vouchers is just as misleading as inventing positive ones.
Review manipulation and price disclosures
- Authority / court
- Federal Trade Commission (FTC)
- Area of law
- Consumer protection and online retail · Fake reviews
- Legal basis
- Section 5 FTC Act; Restore Online Shoppers' Confidence Act (ROSCA)
- Action
- Disgorgement of profits
- Status of proceedings
- final
- Sector
- Healthcare
- Liability of senior managers
- Measures against individuals are not reported here.
- Published
- 3 Dec 2025
Original amount 150,000 USD, converted at the ECB reference rate of 3 Dec 2025.
- FTC Takes Action Against Telemedicine Firm NextMed Press release of an authority
- FTC Approves Final Order against Telehealth Provider NextMed (03.12.2025) Press release of an authority
Checked against the official source on 28 Sep 2026 · Version 3 · Direct link
Report an error
26 Jun 2025 NUWAY Alliance, Inc.NUWAY Alliance: USD 18.5m over payments to Medicaid patients and double billing €15.8m
The Minnesota provider of outpatient addiction treatment pays USD 18,500,000 to resolve False Claims Act allegations and entered into a five-year Corporate Integrity Agreement with HHS-OIG. According to the US Attorney's Office, from January 2019 to February 2025 NUWAY compensated Medicaid patients for attending intensive outpatient treatment and also billed services in which the same period of time was counted twice. The authority allegedly made the findings set out here; this account is not based on a final judgment.
Cash or in-kind incentives to patients for using reimbursable services are prohibited kickbacks under US law.
Incentives to patients for using reimbursable services
- Authority / court
- U.S. Attorney's Office, District of Minnesota (U.S. Department of Justice)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- False Claims Act; Anti-Kickback Statute
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Published
- 26 Jun 2025
Original amount 18,500,000 USD, converted at the ECB reference rate of 26 Jun 2025.
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
23 Jan 2025 C.R. Bard, Inc.; Liberator Medical Supply, Inc.; Liberator Holdings; Rochester Medical CorporationC.R. Bard: USD 17m over discounts and free samples for urology practices €16.3m
Bard and three affiliated companies pay USD 17 million to resolve allegations under the federal False Claims Act and several state statutes. Between 2016 and February 2020 they allegedly gave urology practices discounts, excessive free samples and savings on office supplies so that they would prescribe intermittent catheters by default using Bard's own “Link” prescription form; no liability was determined.
Free samples and discounts must never be linked to prescribing routes that benefit one's own sales.
Free samples and discounts in medical device sales
- Authority / court
- U.S. Attorney's Office, Northern District of Georgia (U.S. Department of Justice)
- Area of law
- Bribery and corruption · Gifts, hospitality and benefits
- Legal basis
- False Claims Act; Anti-Kickback Statute (42 U.S.C. § 1320a-7b); False-Claims-Gesetze mehrerer Bundesstaaten
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Published
- 23 Jan 2025
Original amount 17,000,000 USD, converted at the ECB reference rate of 23 Jan 2025.
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
16 Dec 2024 Becton, Dickinson and Company (BD)Becton Dickinson: risks of Alaris infusion pump concealed – 175 million USD €166.7m
The medical technology manufacturer misled investors about regulatory risks of the Alaris infusion pump, which had more than 25 software defects, and did not record the remediation costs, as a result of which operating income in the fourth quarter of 2019 was overstated by 82 %. BD is paying 175 million USD and must appoint an independent compliance consultant.
Product and approval problems are capital market issues: quality and regulatory affairs departments must be involved in the disclosure process.
- Authority / court
- U.S. Securities and Exchange Commission (SEC)
- Area of law
- Capital markets and financial supervision · Disclosure and reporting obligations
- Legal basis
- Antifraud-, Reporting-, Buchführungs-, interne Kontroll- und Disclosure-Controls-Vorschriften der US-Wertpapiergesetze
- Action
- Fine
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 175,000,000 USD, converted at the ECB reference rate of 16 Dec 2024.
- Becton Dickinson to Pay $175 Million for Misleading Investors About Alaris Infusion Pump Press release of an authority
Checked against the official source on 28 Sep 2026 · Version 2 · Direct link
Report an error
12 Dec 2024 Oroville HospitalOroville Hospital: USD 10.25m over admission bonuses for doctors and false billing €9.77m
The Californian hospital pays USD 10,250,000 (USD 9,518,954 to the federal government, USD 731,046 to the State of California) and entered into a five-year Corporate Integrity Agreement with HHS-OIG. The allegations were that it paid doctors who decided on inpatient admissions bonuses based on the number of patients admitted, billed medically unnecessary inpatient admissions and used false diagnosis codes for SIRS. The authority allegedly made the findings set out here; this account is not based on a final judgment.
Bonus schemes for doctors must not be linked to the number of admissions or referrals.
Bonus schemes for doctors and referral incentives in hospitals
- Authority / court
- U.S. Attorney's Office, Eastern District of California (U.S. Department of Justice)
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- False Claims Act; Anti-Kickback Statute
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Published
- 12 Dec 2024
Original amount 10,250,000 USD, converted at the ECB reference rate of 12 Dec 2024.
Checked against the official source on 3 Oct 2026 · Direct link
Report an error
9 Sep 2024 a US healthcare companySEC: healthcare company pays 1,386,000 USD over waivers of whistleblower awards €1.26m
Between July 2019 and July 2023, the healthcare company had employees waive potential awards for reports to authorities in 98 employment, separation, retention and settlement agreements; in 56 further separation and settlement agreements, they had to waive complaints to federal authorities. As part of a sweep against seven listed companies, the company paid 1,386,000 US dollars to the U.S. Securities and Exchange Commission (SEC); the contract templates were amended.
Separation and employment agreements must restrict neither reports to authorities nor the entitlement to whistleblower awards.
Whistleblower protection in contract templates (HR/Legal)
- Authority / court
- U.S. Securities and Exchange Commission
- Area of law
- Whistleblower protection · Retaliation against whistleblowers
- Legal basis
- Securities Exchange Act of 1934, Rule 21F-17(a)
- Action
- Fine
- Status of proceedings
- final
- Sector
- Healthcare
- Mitigating circumstances
- Partial amendment of the templates even before contact by the SEC, information provided to those affected, and cooperation
- Published
- 9 Sep 2024
Original amount 1,386,000 USD, converted at the ECB reference rate of 9 Sep 2024.
- SEC, Pressemitteilungen (Übersicht) (Entscheidung 2024) Press release of an authority
- SEC, Administrative Proceedings (Übersicht) (Entscheidung 2024) Decision of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 9 Sep 2026 · Direct link
Report an error
21 Aug 2024 a US provider of generative AI for hospitalsTexas obliges AI provider for hospitals to give honest accuracy claims Order
The Texas Attorney General's office concluded an Assurance of Voluntary Compliance with a Texas-based provider of generative AI for hospitals and submitted it to the court for approval. The provider had advertised the accuracy of its software, which summarises patient data for hospital staff, including with a 'severe hallucination' rate of less than 1 in 100,000; the authority considered these metrics likely to be inaccurate and misleading. For five years the provider must clearly explain such metrics in its advertising or have them substantiated by an independent auditor, and must disclose to its customers the risks, limitations and appropriate use of its products; the company denies any wrongdoing, and no payment is provided for.
Reliability metrics for AI need a disclosed definition and measurement method – and users must know when they should not rely on the system.
Performance claims for AI systems; limitations and appropriate use of AI in clinical practice
- Authority / court
- Office of the Attorney General of Texas, Consumer Protection Division
- Area of law
- AI and digital regulation · AI systems
- Legal basis
- Texas Deceptive Trade Practices–Consumer Protection Act (DTPA), Tex. Bus. & Com. Code §§ 17.41–17.63; Zusicherung nach § 17.58
- Action
- Order
- Status of proceedings
- unknown
- Sector
- Healthcare
- Published
- 18 Sep 2024
Checked against the official source on 8 Oct 2026 · Company name anonymised since 21 Aug 2026 · Direct link
Report an error
18 Jul 2024 a major US dialysis groupUS dialysis group: 34.5 million USD – kickbacks for referrals to dialysis centres and pharmacy €31.6m
The dialysis group allegedly paid kickbacks to promote referrals to its former pharmacy subsidiary and granted benefits to nephrologists and vascular surgeons to induce them to send patients to the group's dialysis centres. The group paid 34,487,390 USD.
Intra-group routing of customers to subsidiaries must not be bought with benefits for third parties.
Benefits for referrers
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Employees
- 10,000 or more
Original amount 34,487,390 USD, converted at the ECB reference rate of 18 Jul 2024.
- HHS OIG, Enforcement Actions (Übersicht) (Entscheidung 2024) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 18 Jul 2026 · Direct link
Report an error
1 Jul 2024 three US home health agencies and their parent companyUS home health group: 4.5 million USD – kickbacks to senior living facilities and physicians €4.18m
Three home health agencies in Texas, Ohio and Indiana and their parent company allegedly granted kickbacks to assisted living facilities and physicians for Medicare referrals. They paid 4,496,330 USD.
Cooperation with facilities that refer customers requires written contracts with remuneration at market rates and regular review.
Benefits for cooperation partners who refer customers
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 4,496,330 USD, converted at the ECB reference rate of 1 Jul 2024.
- HHS OIG, Enforcement Actions (Übersicht) (Entscheidung 2024) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 1 Jul 2026 · Direct link
Report an error
12 Jun 2024 a Californian care facilityCalifornian care facility: 658,948 USD – care workers up to 24 hours without breaks €612,121
At the care facility, employees worked up to 24 hours a day, seven days a week, were not allowed to leave the premises, had to work through breaks and received no overtime pay. The settlement of 658,948 USD comprises 608,948 USD for 34 employees (including overtime and break premiums) and 50,000 USD in civil penalties.
Round-the-clock shifts without rest periods are a recurring pattern in care – rosters need checks against maximum working hours and breaks.
Working time limits and breaks in care
- Authority / court
- California Labor Commissioner's Office (Division of Labor Standards Enforcement)
- Area of law
- Health and safety and employment law · Working time
- Legal basis
- California Labor Code (Überstunden, Meal and Rest Periods, Mindestlohn)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
Original amount 658,948 USD, converted at the ECB reference rate of 12 Jun 2024.
- California DIR, Medienraum (Übersicht) (Entscheidung 2024) Press release of an authority
Checked against the official source on 28 Sep 2026 · Version 4 · Company name anonymised since 12 Jun 2026 · Direct link
Report an error
29 May 2024 a US manufacturer of spinal implantsUS implant manufacturer: 12 million USD – kickbacks to spine surgeons €11.1m
The Utah manufacturer of spinal implants allegedly paid surgeons kickbacks to induce them to use the manufacturer's products. The settlement of 12 million USD is a joint payment by the company and other settling parties; HHS-OIG placed the company under heightened scrutiny.
Consultancy agreements, royalty payments or fees to users who decide on the use of products require proof of need and a fair market value review.
Payments to users of medical devices
- Authority / court
- U.S. Department of Justice
- Area of law
- Bribery and corruption · Commercial bribery
- Legal basis
- Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)); False Claims Act (31 U.S.C. §§ 3729 ff.)
- Action
- Other
- Status of proceedings
- final
- Sector
- Healthcare
- Liability of senior managers
- Measures against individuals are not reported here.
Original amount 12,000,000 USD, converted at the ECB reference rate of 29 May 2024.
- HHS OIG, Enforcement Actions (Übersicht) (Entscheidung 2024) Enforcement database of an authority
Checked against the official source on 28 Sep 2026 · Version 6 · Company name anonymised since 29 May 2026 · Direct link